In vivo and in vitro pharmacological studies of aminoglutethimide as an aromatase inhibitor

R. J. Santen, S. J. Santner, N. Tilsen-Mallett, H. R. Rosen, E. Samojlik, Johannes D Veldhuis

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Use of steroid biosynthesis inhibitors to suppress estrogen production is a logical strategy in the treatment of women with hormone-dependent breast cancer. The clinical availability of aminoglutethimide as an inhibitor of cytochrome P-450-mediated steroid hydroxylations prompted study of the precise pharmacological and biochemical effects of this drug. Pharmacokinetic studies revealed that aminoglutethimide alters its own metabolic clearance rate as well as that of dexamethasone, a synthetic glucocorticoid. The metabolic clearance rates of other steroids such as hydrocortisone, medroxyprogesterone acetate, androstenedione, and estrone are not altered by aminoglutethimide. These findings led to the development of a practical regimen of escalating aminoglutethimide dosage in combination with hydrocortisone for treatment of patients with breast carcinoma. Further studies focused upon the biochemical mechanism of estrogen suppression with aminoglutethimide. In vivo, isotopic kinetic data demonstrated that aminoglutethimide inhibits peripheral aromatase by 95 to 98% in postmenopausal women. In vitro experiments indicated that aminoglutethimide can effectively block aromatase directly in human breast tumors as well. With respect to relative potency, aminoglutethimide is a 10-fold more potent aromatase inhibitor than is testololactone but is less potent than are 4-hydroxyandrostenedione and several brominated androstenedione derivatives. Taken together, these studies suggest that aminoglutethimide blocks estrogen production at three sites in women with breast carcinoma: the adrenal cortex, extraglandular peripheral tissues containing aromatase, and breast carcinoma tissue itself.

Original languageEnglish (US)
JournalCancer Research
Volume42
Issue number8 Suppl.
StatePublished - 1982
Externally publishedYes

Fingerprint

Aminoglutethimide
Aromatase Inhibitors
Pharmacology
Aromatase
Breast Neoplasms
Metabolic Clearance Rate
Estrogens
hydrocortisone acetate
Androstenedione
Steroids
In Vitro Techniques
Medroxyprogesterone Acetate
Estrone
Adrenal Cortex
Hydroxylation
Dexamethasone
Glucocorticoids
Hydrocortisone
Pharmacokinetics
Hormones

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Santen, R. J., Santner, S. J., Tilsen-Mallett, N., Rosen, H. R., Samojlik, E., & Veldhuis, J. D. (1982). In vivo and in vitro pharmacological studies of aminoglutethimide as an aromatase inhibitor. Cancer Research, 42(8 Suppl.).

In vivo and in vitro pharmacological studies of aminoglutethimide as an aromatase inhibitor. / Santen, R. J.; Santner, S. J.; Tilsen-Mallett, N.; Rosen, H. R.; Samojlik, E.; Veldhuis, Johannes D.

In: Cancer Research, Vol. 42, No. 8 Suppl., 1982.

Research output: Contribution to journalArticle

Santen, RJ, Santner, SJ, Tilsen-Mallett, N, Rosen, HR, Samojlik, E & Veldhuis, JD 1982, 'In vivo and in vitro pharmacological studies of aminoglutethimide as an aromatase inhibitor', Cancer Research, vol. 42, no. 8 Suppl..
Santen RJ, Santner SJ, Tilsen-Mallett N, Rosen HR, Samojlik E, Veldhuis JD. In vivo and in vitro pharmacological studies of aminoglutethimide as an aromatase inhibitor. Cancer Research. 1982;42(8 Suppl.).
Santen, R. J. ; Santner, S. J. ; Tilsen-Mallett, N. ; Rosen, H. R. ; Samojlik, E. ; Veldhuis, Johannes D. / In vivo and in vitro pharmacological studies of aminoglutethimide as an aromatase inhibitor. In: Cancer Research. 1982 ; Vol. 42, No. 8 Suppl.
@article{f302287c03784ca090a0d3676271d5c9,
title = "In vivo and in vitro pharmacological studies of aminoglutethimide as an aromatase inhibitor",
abstract = "Use of steroid biosynthesis inhibitors to suppress estrogen production is a logical strategy in the treatment of women with hormone-dependent breast cancer. The clinical availability of aminoglutethimide as an inhibitor of cytochrome P-450-mediated steroid hydroxylations prompted study of the precise pharmacological and biochemical effects of this drug. Pharmacokinetic studies revealed that aminoglutethimide alters its own metabolic clearance rate as well as that of dexamethasone, a synthetic glucocorticoid. The metabolic clearance rates of other steroids such as hydrocortisone, medroxyprogesterone acetate, androstenedione, and estrone are not altered by aminoglutethimide. These findings led to the development of a practical regimen of escalating aminoglutethimide dosage in combination with hydrocortisone for treatment of patients with breast carcinoma. Further studies focused upon the biochemical mechanism of estrogen suppression with aminoglutethimide. In vivo, isotopic kinetic data demonstrated that aminoglutethimide inhibits peripheral aromatase by 95 to 98{\%} in postmenopausal women. In vitro experiments indicated that aminoglutethimide can effectively block aromatase directly in human breast tumors as well. With respect to relative potency, aminoglutethimide is a 10-fold more potent aromatase inhibitor than is testololactone but is less potent than are 4-hydroxyandrostenedione and several brominated androstenedione derivatives. Taken together, these studies suggest that aminoglutethimide blocks estrogen production at three sites in women with breast carcinoma: the adrenal cortex, extraglandular peripheral tissues containing aromatase, and breast carcinoma tissue itself.",
author = "Santen, {R. J.} and Santner, {S. J.} and N. Tilsen-Mallett and Rosen, {H. R.} and E. Samojlik and Veldhuis, {Johannes D}",
year = "1982",
language = "English (US)",
volume = "42",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "8 Suppl.",

}

TY - JOUR

T1 - In vivo and in vitro pharmacological studies of aminoglutethimide as an aromatase inhibitor

AU - Santen, R. J.

AU - Santner, S. J.

AU - Tilsen-Mallett, N.

AU - Rosen, H. R.

AU - Samojlik, E.

AU - Veldhuis, Johannes D

PY - 1982

Y1 - 1982

N2 - Use of steroid biosynthesis inhibitors to suppress estrogen production is a logical strategy in the treatment of women with hormone-dependent breast cancer. The clinical availability of aminoglutethimide as an inhibitor of cytochrome P-450-mediated steroid hydroxylations prompted study of the precise pharmacological and biochemical effects of this drug. Pharmacokinetic studies revealed that aminoglutethimide alters its own metabolic clearance rate as well as that of dexamethasone, a synthetic glucocorticoid. The metabolic clearance rates of other steroids such as hydrocortisone, medroxyprogesterone acetate, androstenedione, and estrone are not altered by aminoglutethimide. These findings led to the development of a practical regimen of escalating aminoglutethimide dosage in combination with hydrocortisone for treatment of patients with breast carcinoma. Further studies focused upon the biochemical mechanism of estrogen suppression with aminoglutethimide. In vivo, isotopic kinetic data demonstrated that aminoglutethimide inhibits peripheral aromatase by 95 to 98% in postmenopausal women. In vitro experiments indicated that aminoglutethimide can effectively block aromatase directly in human breast tumors as well. With respect to relative potency, aminoglutethimide is a 10-fold more potent aromatase inhibitor than is testololactone but is less potent than are 4-hydroxyandrostenedione and several brominated androstenedione derivatives. Taken together, these studies suggest that aminoglutethimide blocks estrogen production at three sites in women with breast carcinoma: the adrenal cortex, extraglandular peripheral tissues containing aromatase, and breast carcinoma tissue itself.

AB - Use of steroid biosynthesis inhibitors to suppress estrogen production is a logical strategy in the treatment of women with hormone-dependent breast cancer. The clinical availability of aminoglutethimide as an inhibitor of cytochrome P-450-mediated steroid hydroxylations prompted study of the precise pharmacological and biochemical effects of this drug. Pharmacokinetic studies revealed that aminoglutethimide alters its own metabolic clearance rate as well as that of dexamethasone, a synthetic glucocorticoid. The metabolic clearance rates of other steroids such as hydrocortisone, medroxyprogesterone acetate, androstenedione, and estrone are not altered by aminoglutethimide. These findings led to the development of a practical regimen of escalating aminoglutethimide dosage in combination with hydrocortisone for treatment of patients with breast carcinoma. Further studies focused upon the biochemical mechanism of estrogen suppression with aminoglutethimide. In vivo, isotopic kinetic data demonstrated that aminoglutethimide inhibits peripheral aromatase by 95 to 98% in postmenopausal women. In vitro experiments indicated that aminoglutethimide can effectively block aromatase directly in human breast tumors as well. With respect to relative potency, aminoglutethimide is a 10-fold more potent aromatase inhibitor than is testololactone but is less potent than are 4-hydroxyandrostenedione and several brominated androstenedione derivatives. Taken together, these studies suggest that aminoglutethimide blocks estrogen production at three sites in women with breast carcinoma: the adrenal cortex, extraglandular peripheral tissues containing aromatase, and breast carcinoma tissue itself.

UR - http://www.scopus.com/inward/record.url?scp=0020325108&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020325108&partnerID=8YFLogxK

M3 - Article

C2 - 7083200

AN - SCOPUS:0020325108

VL - 42

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 8 Suppl.

ER -